Masoom Priyadarshini - Bristol Myers Squibb, Princeton

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Economic Burden in Patients (pt) with CLL/SLL (CLL) Who Received ≥ 2 Prior Lines of Therapy (LOT), Including a Bruton Tyrosine Kinase Inhibitor (btki): A SEER-Medicare Analysis

Farrukh Tauseef Awan,Soham Yande, Lizzi Esterberg,Saurabh P. Nagar, Ravi K. Goyal,Masoom Priyadarshini

JCO Oncology Practiceno. 11_suppl (2023): 24-24

引用0浏览0引用

Post-Infusion Monitoring Costs and Health Care Resource Utilization (HCRU) by Site of Care (SOC) in Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 (TRANSCEND) Study

November McGarvey,Abraham Lee,Ken Imanak,Simran K. Tiwana,Sean Garrison,Masoom Priyadarshini

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S516-S517

引用0浏览0引用

The Total Lifetime Cost of Treating Patients (pts) with CLL in the United States (US)

Farrukh T. Awan, Aleksandra Vidisheva, Matia Saeedian, Murat Kurt,Simran K. Tiwana,Masoom Priyadarshini

Bloodno. Supplement 1 (2023): 2330-2330

引用0浏览0引用

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (nes) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (Liso-Cel) Treatment in the TRANSCEND CLL 004 Study

Farrukh T. Awan,November McGarvey,Abraham Lee,Ken Imanak,Simran K. Tiwana,Sean Garrison,Masoom Priyadarshini

Bloodno. Supplement 1 (2023): 7252-7252

引用0浏览0引用

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)

Masoom Priyadarshini, Zaneta Balantac,Simran K. Tiwana,Shweta Bapat,Sean Garrison, Mona L. Martin

HemaSphereno. S3 (2023): e023224f-e023224f

引用0浏览0引用

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)

Masoom Priyadarshini, Gaurav Deshpande,Simran K. Tiwana,Trong Kim Le,Sean Garrison,Farrukh T. Awan

HemaSphereno. S3 (2023): e8677199-e8677199

引用0浏览0引用

Real-World Treatment (tx) Patterns and Clinical Outcomes among Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (btki) And/or B-Cell Lymphoma 2 Inhibitor (Bcl2i)

Farrukh T. Awan, Gaurav A. Deshpande,Trong Kim Le,Sean Garrison,Simran K. Tiwana,Masoom Priyadarshini

Blood（2022）

引用0浏览0引用

Financial Toxicity and Its Impact on Health Outcomes and Caregiver Burden among Adult Cancer Survivors in the USA

Sushmitha Inguva,Masoom Priyadarshini,Ruchit Shah,Kaustuv Bhattacharya

Future oncology（2022）

引用10浏览0WOS引用

Corrigendum: Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States

Masoom Priyadarshini,Vimalanand S. Prabhu,Sonya J. Snedecor,Shelby Corman,Barbara J. Kuter,Chizoba Nwankwo,Diana Chirovsky,Evan Myers

Frontiers in public health (2021)

引用0浏览0引用

Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States

Masoom Priyadarshini,Vimalanand S. Prabhu,Sonya J. Snedecor,Shelby Corman,Barbara J. Kuter,Chizoba Nwankwo,Diana Chirovsky,Evan R. Myers

Frontiers in Public Health（2021）

引用12浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn